Marco Meglio

Using the Wechsler Adult Intelligence Scale Fourth Edition (WAIS-IV) Coding Test score, SAGE-718 failed to distinguish itself from placebo.

Foralumab's anti-CD3 mechanism modulates T cell function, offering potential benefits for the challenging-to-treat na-SPMS patients.

Mark Bain, MD, a neurosurgeon at Cleveland Clinic’s Cerebrovascular Center, provided commentary on the ENRICH trial, a positive study of minimally invasive removal of intracerebral hemorrhage.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the sleep disorders.

Tavapadon's phase 3 success complements ongoing monotherapy trials, addressing the need for effective and well-tolerated PD therapies.

The research grant aims to diversify Friedreich ataxia treatments, addressing challenges in trial design and therapeutic strategies for this condition.

Patients experienced improvements in ON/OFF time and motor function, with favorable tolerability, paving the way for a phase 2 trial.

Mind Moments®, a podcast from NeurologyLive®, brings you an interview with Ian Kremer. [LISTEN TIME: 35 minutes]

Across 2, phase 3 studies, fremanezumab provided significant effects on monthly migraine days, regardless of whether patients were obese or not.

Even when combining both adult and pediatric patients, diazepam nasal spray administered within 5 minutes of a seizure led to quicker seizure termination.

Investigators found no trends in amyloid-imaging abnormality rates based on centile tertile levels for lecanemab-treated patients.

Patients treated with ALZ-801 showed improvements in cognition, reduced brain atrophy, and maintained dementia rating stages.

Over 2, phase 3 studies, brexpiprazole-treated patients demonstrated greater response rates across various levels on the Cohen-Mansfield Agitation Index and Clinical Impression Scale-Improvement assessment.

Combination of atogepant and ubrogepant resulted in minimal adverse events, and were safe and well-tolerated over a 12-week period.

Results showed consistent reductions in monthly migraine days over 48 weeks, with a favorable safety profile observed.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the American Academy of Neurology Annual Meeting.

Patients on riliprubart demonstrated improvements on several measures of disability and impairment, including the INCAT, I-RODS, MRC-SS, and grip strength.

Patients with first MS symptoms less than 3 years prior to enrollment saw greater long-term benefits with ublituximab than those with longer disease course.

In the phase 3 MOMENTUM and INTERCEPT studies, patients treated with AXS-07 saw reductions in headache pain freedom, most bothersome symptoms, and use of rescue medications.

Being a boy, having lower depression and anxiety scores, lower headache intensity, lower affective pain perception, fewer pain locations, fewer sleep issues, and lower pain-related disability predicted headache remission.

Analyzing data from the H70-BCS, researchers identified around 6.2% of 70-year-olds meeting lecanemab treatment criteria, suggesting millions in Europe and the US might be eligible.

All 8 participants met prespecified responder criteria demonstrating either improvement or stabilization of disease according to both the Patient Reported Global Impression of Change and the Clinician Reported Global Impression of Change scales.

At 180 days after surgery, weighted disability scores were better with surgery plus medical management than with medical management alone.

The smartphone tests accurately differentiated individuals with dementia from controls and were more sensitive to early symptoms than the Montreal Cognitive Assessment, a commonly used cognitive screening tool.

The new double-blind, placebo-controlled study includes approximately 200 patients with ALS who will undergo a single bone marrow aspiration procedure to procure the mesenchymal stem cells that will be used to manufacture each participant’s NurOwn treatment for the trial.

The new position statement proposes the use of CGRP-targeting therapies to be used as first-line treatments, eliminating the need to fail multiple medications before access.

The newly initiated phase 3 trial follows a successful phase 2 study where treatment with pitolisant resulted in greater improvement on the Epworth Sleepiness Scale for Children and Adolescents than placebo.

Therapeutic effects were noticeable within 15–20 days post-injection, with five of six patients achieving complete pain relief.

Ganaxolone, a synthetic neurosteroid, has ongoing studies in tuberous sclerosis complex and super refractory status epilepticus, as well as upcoming research in Lennox-Gastaut syndrome and other epileptic encephalopathies.

SPN-830, an apomorphine infusion device, had its new drug application submitted using data from the phase 3 TOLEDO trial.